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Abstract : In this review paper, the authors analyse
advantages, pitfalls and economical considerations relat-
ed to depth of anaesthesia monitoring. They first describe
the most widely distributed monitors in Europe, and the
physiological basis of each index. The optimal use of
those monitors and their demonstrated clinical benefits
are detailed, as well as the circumstances that can lead to
erroneous information or interpretation. Knowledge of
patients and practitioners, as well as beliefs and expecta-
tions regarding depth of anaesthesia monitoring are dis-
cussed. Finally, the authors give their own opinion regard-
ing the use of depth of anaesthesia monitoring, according
to clinical benefit and economical considerations.
Key words : Monitoring ; depth of anaesthesia ; clinical
use ; economics.
INTRODUCTION
Several commercially available cerebral mon-
itoring devices are currently capable to provide at
the bedside a series of parameters that reflect on
line either the physiological or the pathological
brain state. They are the most often divided into two
categories, the depth of anaesthesia monitors and
the monitors used to explore the suffering brain.
Some of those monitors have been recently set up
thanks to sophisticated new technologies. The cost
associated to their use may be high and, in the cur-
rent context of financial healthcare budget restric-
tions, their cost-benefit ratio is a matter of great
concern. Settling such an important issue requires
good knowledge about what is exactly measured by
each device, the evidence-based advantages of
using those techniques in relation with the patients
outcome, in terms of patient care-related cost sav-
ings, if any, and, finally about the real cost of their
use. In the present review paper, we will address all
these points according to available data and restrict
the discussion to monitors dedicated to depth of
anaesthesia monitoring.
DEPTH OF ANAESTHESIA MONITORS
Depth of anaesthesia monitoring consists in
measuring the dose-concentration-response rela-
tionship between anaesthetic agents and their main
pharmacodynamic effects (1). Because those
effects are numerous, the definition of depth of
anaesthesia will depend on the considered pharma-
codynamic component : the level of wakefulness/
awareness (i.e. the level of hypnosis), the nocicep-
tive-anti-nociceptive balance, the level of muscle
relaxation or other components can be considered
in that respect. The evaluation of any pharmacody-
namic component of anaesthesia by clinical means
is poorly sensitive and specific. Signs such as ven-
tilation rate, pupil diameter, eyelash reflex, swal-
lowing reflex, muscular tone, movements, blood
pressure, heart rate, tearing, sweating, and response
to verbal command are to be checked by the anaes-
thesiologist at regular intervals but poorly discrimi-
nate between the components of anaesthesia.
Furthermore, the study of the pharmacodynamic
effects of anaesthesia is made complex due to inter-
actions between those effects (e.g. the level of hyp-
nosis is modulated by the level of nociceptive stim-
ulation), variability of pharmacodynamic effects
between classes of anaesthetic agents, and interac-
tions between those agents. Hence, several attempts
to overcome the problem of poor sensitivity and
specificity have led to the development of specific
indices designed to monitor a given pharmacody-
namic effect of anaesthesia. Most of these attempts
were primarily devoted to the hypnotic component
of anaesthesia (depth of the hypnotic component of
anaesthesia monitors, DHCA monitors). The
description of the most widely distributed of them
in Europe follows.
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The Bispectral Index™ (Aspect Medical System,
Inc.)
The Bispectral Index (BIS™) is the first
DHCA monitor introduced on the market, and is
probably the most widely used and studied. It
ranges between 0 and 100 arbitrary units. It relies
on a complex mathematical analysis of the elec-
troencephalogram (EEG). The algorithm extracts
several EEG parameters such as the power spec-
trum, the activity in the b frequency range, the burst
suppression activity, the synchronised fast slow
activity, and the bispectrum, which quantifies inter-
frequency phase relationships (2). Each parameter
is associated with a factor whose weight depends on
the hypnotic level. Schematically, a BIS value
between 100 and 60 mainly varies according to the
b activity, between 60 and 40 according to the syn-
chronised fast slow activity, between 40 and 20
according to the proportion of quasi-flat EEG activ-
ity, and between 20 and 0 according to the suppres-
sion ratio. The BIS algorithm has changed from its
initial version to improve artefacts rejection and
reliability. Fully awake patients have a BIS value
above 93. Loss of consciousness usually occurs at
80. A BIS value between 40 and 60 is recommend-
ed during anaesthesia (3, 4). This monitor is either
available as a separate monitor (Aspect A2000
BIS™ monitor) or as a module that can be part of a
Datex-Ohmeda monitor (BIS™ module, Datex-
Ohmeda, Inc.). The delay between signal acquisi-
tion and the value display on the screen is variable
and in the range of 30 seconds, although it has been
shortened in the most recent version of the monitor.
In the presence of artefacts, this delay can be as
long as 60 seconds. The user can choose to smooth
the values displayed on the screen over 15 or
30 seconds. The BIS™ provides a signal quality
index (SQI) which gives an idea about the number
of rejected EEG sequences because of artefacts, and
about the reliability of the index at a given time.
Several other parameters are available through ade-
quate selection of screen display such as the spec-
tral edge frequency of the EEG or an estimation of
the electromyographic activity. An EEG raw tracing
can also be displayed on the screen.
The A-Line Autoregressive Index (Danmeter A/S,
Odense, Denmark)
The A-Line Autoregressive Index (AAI™) is
obtained through the recording of middle latency
auditory evoked potentials (auditory middle latency
response, AMLR) consisting in three main peaks
Na, Pa and Nb. The amplitude of those peaks
decreases and their phase increases with increasing
concentrations of hypnotic agents (5). The monitor
uses advanced signal processing, namely an autore-
gressive modelling with exogenous input to extract
the signal quickly. AAI™ is defined as the sum of
absolute differences in the 20-80 millisecond win-
dow of the AMLR (6) and resized into an index
ranging between 0 and 100. The delay for obtaining
the AAI averages 1.7 seconds (7). The current ver-
sion of this monitor (AEP-Monitor/2) calculates a
composite index based on the AMLR and on
parameters of the processed EEG (8). Little is cur-
rently known about the clinical significance of this
new index. Finally, the combined use of BIS and
AAI indices may provide some information about
the adequacy of the nociceptive-anti-nociceptive
balance during anaesthesia, the BIS serving to tar-
get a hypnotic level while the AAI response to a
nociceptive stimulation allows the practioner to
evaluate the degree of adequacy of the nociceptive-
anti-nociceptive balance (9).
The Spectral Entropy of the EEG
The entropy of a system is a measure of the
disorder encountered in this system. Shannon first
applied this principle to the analysis of a sig-
nal (10). The entropy applied to the EEG and to
DHCA monitoring relies on the assumption that the
EEG of an anaesthetised patient would be more reg-
ular (low entropy) than the one of an awake patient
(high entropy). The M-Entropy™ module imple-
mented on the S/5™ Anaesthesia Monitor (GE
Healthcare, Finland) proceeds to a time domain and
frequency domain analysis of the EEG. It first com-
putes a Fourier transform of the signal and gener-
ates a power spectrum. The Shannon function is
then applied to the power spectrum to obtain a
scale-invariant number, independent of the frequen-
cy and amplitude scales of the signal. This number
is normalised. The length of the time window for
entropy calculation varies according to frequencies
that predominate in the power spectrum (range : 2-
60 seconds). The window is short for high frequen-
cies and longer for low frequencies (time-frequency
balanced analysis). Therefore, numbers will be dis-
played more rapidly but the delay for obtaining the
entropy value will be longer at deeper stages of
anaesthesia. The M-Entropy™ monitor has been
designed for advanced artefact rejection such as
electrocautery, ECG and pacing, eye movements
and blinking, as well as movement artefacts. The
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analysis is performed on two different frequency
ranges, the 0.8-32 Hz band, which predominantly
contains EEG signals, and the 0.8-47 Hz band,
which includes the frequencies associated to elec-
tromyographic activity of facial muscles. Hence,
the monitor provides two entropy values, the State
Entropy (SE) and the Response Entropy (RE). SE
ranges between 0 and 91 and would reflect depth of
hypnosis, or the cortical state. RE ranges between 0
and 100 and is thought to reflect the nociceptive-
anti-nociceptive balance. In case of nociceptive
stimulation and inadequate analgesia, facial EMG
activity increases, and RE increases. Therefore, RE
is always higher than SE, except when there is no
facial EMG activity. In that case, RE and SE are
equal. The manufacturer recommends that the hyp-
notic component of anaesthesia should be adjusted
according to SE, which should remain under 60,
and that an increase in RE or in the RE-SE gradient
should prompt the anaesthesiologist to improve the
anti-nociceptive component of anaesthesia (11).
However, validation studies are needed to better
define the role of RE and RE-SE gradient in appre-
ciating the nociceptive-anti-nociceptive bal-
ance (12), and particularly the influence of muscle
relaxation on this ability (13).
The Narcotrend™
The Narcotrend™ monitor (Monitor Technik,
Germany, and Schiller, Switzerland) is another
EEG-based monitor of the hypnotic component of
anaesthesia. The development of the algorithm was
based on 6 different EEG patterns corresponding to
sleep stages, which were further divided into sub
stages, leading to a total of 15 stages. Those stages
correspond to EEG patterns that can be visually
observed during volatile and intravenous anaesthe-
sia (14). The monitor extracts several EEG parame-
ters including spectral parameters, entropy meas-
ures, and autoregressive parameters, that best dis-
criminate between those stages. Those parameters
are combined into an index ranging between 0 and
100. The monitor displays the value of the index
and a letter corresponding to the stage of anaesthe-
sia (A and B0 = awake, B1-2 = sedated, C0-2 = light
anaesthesia, D0-2 = general anaesthesia, E0-2 = gener-
al anaesthesia with deep hypnosis, F0-1 = general
anaesthesia with increasing burst suppression). A
Narcotrend™ stage D is recommended during sur-
gery. Unlike other monitors, the Narcotrend™ does
not require specific sensors and works with simple
ECG electrodes.
The Patient State Index™
The PSA 4000™ and SedLine™ monitors
(Hospira, USA) are monitors capable of calculating
the Patient State Index™ (PSI™) which is also an
index of the hypnotic component of anaesthesia,
and, hence, of the cortical state. Its value ranges
between 0 and 100. The algorithm incorporates a
combination of EEG parameters sensitive to
changes in depth of hypnosis, but independent of
medication combination (15) : power of several
EEG frequency bands, symmetry and synchronisa-
tion between brain regions, and activity in regions
of the frontal cortex are quantified. A specific set of
four EEG electrodes and a ground electrode are
required.
The SNAP Index™
Among the algorithm developed to calculate
indices reflecting the cortical state, the one of the
SNAP Index™ is probably the most simple. The
device, implemented on a Personal Digital Assistant
system, analyses the EEG upon a large frequency
range (from 0.1 to 420 Hz). After a Fast Fourier
Transform, it divides the power spectrum into two
components, the high-frequency component (80-
420 Hz) and the low-frequency component (0.1-
40 Hz). The high frequency component is scaled to
result in values ranging between 0 and 1, and the
low-frequency one to values between 0 and 100.
The index is obtained according to the following
formula : SNAP Index™ = 100 – (high-frequency
X low-frequency) (16), leading to a value ranging
between 0 and 100. A value of 50-65 is recom-
mended during surgery (17). Unfortunately, this
index still deserves validation studies before recom-
mendation for clinical practice. In particular, the
question of the influence of EMG activity and mus-
cle relaxation needs to be clarified.
Other and future monitors
Simplified EEG monitors, such as the M-
EEG™ module (GE Healthcare, Finland), are not
directly designed to assess a particular pharmaco-
dynamic component of anaesthesia but display sev-
eral parameters derived from the spectral analysis
of the EEG such as the spectral edge frequency
(SEF), the median frequency, or the relative power
in the frequency bands b, a, q, and d. Those param-
eters can provide information about the depth of
hypnosis, although it has been demonstrated that
MEF and SEF are less reliable measures of the
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depth of hypnosis than the BIS™ or the
Narcotrend™ (18). An advantage of those monitors
over those described above is that a larger portion of
the scalp is explored. This can be interesting to
detect adverse events such as cerebral ischemia dur-
ing carotid surgery, intracranial aneurysm surgery,
or cardiac surgery (19), or the occurrence of some
epileptic seizure.
Other devices currently under development are
promising. The NeuroSENSE™ monitor
(CleveMed, USA) is a monitor of the hypnotic
component of anaesthesia. It is based on the quan-
tification of cortical activity using wavelet analy-
sis (20). This device beneficiates from advanced
artefact rejection and a short reactive time com-
pared to the BIS. It has still to be validated in clini-
cal practice. The same is also true for the Cerebral
State Index (CSI™, Cerebral State Monitor™,
Danmeter A/S), the algorithm of which has been
developed by using an original statistical approach.
The CSI™ integrates parameters derived from the
spectral analysis of the EEG, as well as the suppres-
sion ratio. It has been demonstrated to be equal to
the BIS™ or the AAI™ at discriminating levels of
sedation (21). Monitors devoted to assess the ade-
quacy of the nociceptive-anti-nociceptive balance
are also under development (22). Most of them are
based on measuring the autonomic response to
nociceptive stimulation, either the pupil response to
light (23), the pulse transit time (24), heart rate or
blood pressure variability (25), the skin vasomotor
reflex (26), the photoplethysmography pulse wave
reflex (27), or a combination of those parame-
ters (28). Finally, it is possible to measure the motor
response to nociceptive stimulation using the
spinal-H reflex (29).
OPTIMAL USE OF DHCA MONITORS
The optimal use of DHCA monitors requires
concomitant knowledge of the concentration of
anaesthetic agents at their effect-site, either by
using target-controlled infusion systems (TCI) or
by monitoring the end-tidal concentration of
volatile anaesthetics. To obtain maximum benefit,
this type of monitoring should be instituted before
induction of anaesthesia. A common way to get rid
of the problem related to interaction between anaes-
thetic agents, which sometimes makes interpreta-
tion of index values difficult, is to start the induc-
tion of anaesthesia with the anti-nociceptive
medications, and ideally to use a TCI system. An
effect-site concentration expected to cover the anti-
nociceptive needs related to endotracheal intubation
and surgical procedure is chosen. Opioids adminis-
trated alone will not affect the value of the index
that much (30). Once a steady-state is achieved, the
administration of the hypnotic medication can be
started. The value of the index at the time of the loss
of consciousness may be noted and serve as a refer-
ence value throughout the course of anaesthesia.
This way of proceeding limits the amount of hyp-
notic medications given to patients, and may theo-
retically increase the risk of unexpected awareness.
However, it has been demonstrated that this proto-
col is not associated with intra-operative explicit or
implicit memories (31). Thereafter, it is also impor-
tant to note the effect of muscle relaxation on the
recorded index (e.g. a decrease in BIS, or a decrease
in RE-SE gradient). Tracheal intubation should be
considered as a relatively standardised nociceptive
stimulus. The response of the recorded index to that
stimulus will provide information about the noci-
ceptive-anti-nociceptive balance (30). The observed
response will be the one observed subsequently for
each stimulation that is at least as intense, provided
that the anti-nociceptive regimen remains the same.
An intense response will prompt the anaesthesiolo-
gist to increase the target concentration of opioids
when he/she expects an intense nociceptive stimula-
tion. In the absence of a specific monitor of the ade-
quacy of the nociceptive-anti-nociceptive balance,
it is important to maintain an appropriate anti-noci-
ceptive level, guided by the expected intensity of
the nociceptive stimulation. This will limit the risk
of titrating hypnotic medications too tightly during
episodes of minimal stimulation (e.g. field prepara-
tion, patient installation), and observing intense
response of the patient, or even awareness, at the
beginning of surgery.
DEMONSTRATED CLINICAL BENEFITS
Several demonstrated clinical benefits of
DHCA monitors are summarised in Table 1. Most
of these advantages have been asserted for the
BIS™, and do not necessarily apply for the other
monitors. It is now established that using the BIS™
significantly reduces the risk of intra operative
awareness (32), particularly in patients at high risk
of experiencing such an unpleasant event. A 82%
reduction in the incidence has been reported for
those patients (33). However, the American Society
of Anaesthesiologists Task Force on Intraoperative
awareness does not recommend the routine use of
DHCA monitors for all patients. According to those
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recommendations, the decision to use a DCHA
monitor should be taken on a case-by-case basis by
the individual practitioner for selected patients (34).
As described above, the optimal use of those moni-
tors combined to an estimation of the effect-site
concentration of anaesthetic agents allows individ-
ual rationalisation of anaesthetic agent administra-
tion, and precludes the anaesthesiologist from over
dosage administration (35). Indeed, blinded record-
ings of BIS™ in patients scheduled to undergo
rapid emergence by the anaesthesiologist in charge
of their general anaesthesia were in the 30-40 range,
corresponding to deep sedation and near burst sup-
pression (4, 32, 33). This is to be pointed out, as a
too deep sedation (and hypotension) cumulative
prolonged period of time has been reported to be
associated with an increased one year mortality (36,
37). Most of the DHCA monitors reduce the
amount of hypnotic medications administered to
patients, and hasten recovery (35, 38-40). Tightness
of titration could even be further improved when
closed-loop devices will be available in routine
practice (41). Thanks to adequate titration, the inci-
dence of postoperative residual side effects such as
drowsiness, dizziness, fatigue, can be reduced (35),
as well as the incidence of nausea and vomiting
after halogenated volatile general anaesthesia (42,
43). Furthermore, the use of DHCA monitors pro-
vides information regarding the adequacy of the
nociceptive-anti-nociceptive balance. Considering
all those clinical benefits, the quality of DHCA-
guided general anaesthesia is undoubtedly
improved compared to conventional practice.
CONDITIONS THAT IMPEDE CORRECT INTERPRETATION OF
DHCA INDICES
Unfortunately, as with any kind of monitor,
several conditions may impede the correct interpre-
tation of DHCA indices (44). Those conditions, that
should be known by the user, are summarised in
Table 2.
Artefacts from surrounding electrical devices
The operating theatre is crowded with a num-
ber of electrical devices. Their use may contaminate
the EEG tracing and artificially modify the EEG-
derived index. The most perturbing one is the elec-
trocautery. The use of this device usually prevents
the monitor to acquire reliable EEG signal and
therefore to calculate an index value. Otherwise,
electrocautery can also artificially increase the
value of the index. Advanced artefact rejection sys-
tems reduce the importance of this problem for
some of the available monitors (M-Entropy™,
PSArray2™, NeuroSENSE™) (20, 45, 46). Other
devices such as atrial pacers, warming blankets,
endoscopic shavers or electromagnetic systems can
also cause troubles (44).
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Table 1
Summary of the clinical advantages when using depth of the hypnotic component of anaesthesia monitors combined to
an estimation of the effect-site concentration of anaesthetic agents
Clinical benefits of using dhca monitors Consequences
Prevention of unexpected intra operative awareness
Sparing effect on hypnotic anaesthetic agents consumption Possible cost savings, not for short procedures
Earlier extubation
Patient comfort and quality of anaesthesia improved
Shorter delays for discharge from post anaesthesia care units
}
Individual rationalisation of anaesthetic agents administration when
combined to effect-site concentration of anaesthetic agents Less under or over dosage of anaesthetic agents
Better global stability
– Effect-site concentration and index value at the time of the loss Reduction in the incidence of postoperative nausea and
of consciousness = reference values vomiting after a DHCA-guided halogenated volatile anaesthesia
– Individual titration of the anti-nociceptive component Potential reduction in residual side effects
of anaesthesia } (drowsiness, dizziness, fatigue)
Better prediction of the time of recovery
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Inter and intra individual variability
It is sometimes not easy to cope with the inter-
individual variability of the recorded indices. For
example, awake baseline values can be highly vari-
able from one subject to another (47). Similarly, the
same anaesthetic regimen will not necessarily lead
to the same DHCA value in two different patients,
and the index response to a given nociceptive stim-
ulation can also differ. This can be attributed to
inter-individual differences in skull impedance,
audition, genetically-determined EEG amplitude,
sensitivity to nociceptive stimulation, and probably
other factors. The best way to overcome this prob-
lem is to work on an individual basis rather than
using absolute reference values. As mentioned
above, observing individual baseline values and the
individual profile of the index during induction of
anaesthesia is very important in that respect. Intra
individual variability of the value of a DHCA index
does exist. Indeed, the same index recorded on two
different sites in the same patients may have differ-
ent values (48).
Interactions between anaesthetic agents
Single drug general anaesthesia is rare.
Practitioners often use a cocktail of medications
designed to encounter hypnotic, anti-nociceptive,
muscle relaxation and autonomic modulation
needs. All those medications have specific proper-
ties. They may influence the DHCA value either
directly or through drug interactions.
As opposed to the well established relation-
ship between DHCA index and effect-site concen-
tration of hypnotic medications, opioids alone poor-
ly influence the value of that index. This is also true
under general anaesthesia with propofol alone in
the absence of nociceptive stimulation (49, 50).
When a nociceptive stimulus is applied, the value of
the DHCA index associated with the absence of
Table 2
Summary of  different conditions which may impede correct interpretation of DHCA index values. Adapted from Dahaba (44)
Condition Effect on DHCA index Explanation
Surrounding electrical devices
– Electrocautery, atrial pacers, warming
blankets, endoscopic shavers,
electromagnetic systems, ...
– No index displayed
– Artificial increase/decrease
– Bad quality EEG signal
– High/low frequency contamination
Subject variability
– Inter individual variability
– Intra individual variability
– Skull impedance, audition, genetically-
determined EEG amplitudes, sensitivity to
nociceptive stimulation, …
– Site of recording







– Weak effect alone or with hypnotic agents if nocicep-
tive stimulation absent
– Modification of response to nociceptive stimulation
– Paradoxical increase (abrupt increase in concentration)
– No effect alone
– Increase during hypnotic-opioid anaesthesia
– Weak effect alone or with hypnotic agents if nocicep-
tive stimulation absent
– Decrease during hypnotic-opioid anaesthesia in the
presence of nociceptive stimulation
– Decrease although having a similar mechanism of
action as nitrous oxide and ketamine
– Reveal falsely elevated index
– Decrease of the index
– Decrease RE and RE-SE response to nociceptive
stimulation
– Weak hypnotic effect
– Suppression of arousal effect of stimulation
– Particular EEG patterns
– Excitatory effect on the EEG
– Do not slow down EEG activity
– Suppression of arousal effect of nociceptive
stimulation
– Suppression of cortical activity
– Suppression of EMG contamination
– Decrease in muscle-generated sensory
inputs
– Decrease in EMG 
Specific clinical conditions
– Hypothermia, hypoglycaemia,
Alzheimer dementia, cerebral palsy,
genetically low voltage EEG, post-ictal




– Low EEG activity
– ?
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movement in the majority of patients depends on
the hypnotic-anti-nociceptive combination.
Schematically, this threshold value will be higher
when the opioid concentration is high and the hyp-
notic concentration low than in the inverse situation
(opioid low and hypnotic high) (50).
Paradoxical increases in BIS™ have been
reported following abrupt increases in halothane or
isoflurane in the inspired gases (51-53). This effect
is not observed with sevoflurane and may be due to
specific EEG patterns induced by those agents at
clinical concentrations. Therefore, monitoring the
depth of hypnosis using BIS during halothane or
isoflurane anaesthesia may lead to inadvertent over-
dosage of these medications (44).
Ketamine administered alone at a dose suffi-
cient to produce unresponsiveness does not reduce
BIS™. When administered during sevoflurane-
sufentanil anaesthesia, ketamine has been demon-
strated to paradoxically increase BIS™ and
entropy (54), and the amplitude of the AMLR (55).
This drug is acknowledged as a dissociative anaes-
thetic with excitatory effects on the EEG, that could
explain those paradoxical changes (2). Similarly,
nitrous oxide does not affect BIS™ and entropy
value when administered alone or under general
anaesthesia in the absence of nociceptive stimula-
tion, but does decrease BIS™ when that stimulation
is present (56). Although having a similar mecha-
nism of action as ketamine and nitrous oxide, that is
inhibiting N-methyl-D-aspartate receptors, xenon
does not have the same effects on DHCA indices. It
decreases the BIS™ and the AMLR in a concentra-
tion-dependent manner (57).
The degree of muscle relaxation may influ-
ence the value of the DHCA index by two mecha-
nisms. Muscle relaxation by itself decreases mus-
cle-generated sensory inputs to the brain, and hence
the level of arousal (58). Depending on the frequen-
cy band included in the calculation algorithm, EMG
activity may also be a determinant factor of the
DHCA value. It has been shown to falsely elevate
BIS™ value (59-61). The effects of neuromuscular
blocking agents on DHCA monitoring probably
depend on the background anaesthetic level, and
may be less marked at deep levels of anaesthesia.
Indeed, in those circumstances, central afferenta-
tion and EMG activity are depressed by anaesthetic
agents. This would explain why it has been report-
ed that antagonism of neuromuscular block but not
muscle relaxation affects the depth of anaesthe-
sia (62). Muscle relaxation has also been demon-
strated to attenuate the RE and RE-SE response to
nociceptive stimulation (13).
Specific clinical conditions
Several particular clinical conditions may also
modify DHCA values. Hypothermia and hypogly-
caemia decrease BIS™. Low BIS™ values have
been reported in patients with Alzheimer dementia,
cerebral palsy, genetically determined low voltage
EEG and in the post-ictal phase of seizures (44).
Cerebral ischemia and cardiac arrest produce a sud-
den decrease in BIS™ of high amplitude (63-66).
Finally, in the absence of cerebral ischemia, carotid
clamping may be associated to a paradoxical tran-
sient increase in BIS™, particularly in patients with
poor contralateral blood supply to the brain (67).
AGREEMENT BETWEEN DIFFERENT INDICES
Comparison of measurement techniques can
rely on the calculation of their respective correla-
tion coefficients or prediction probability values
with pharmacokinetic or pharmacodynamic param-
eters. In that way, each technique is evaluated on its
own behalf and its global performance is compared
with that of others (47, 49). The vast majority of
DHCA indices do perform well in assessing depth
of hypnosis as estimated by clinical scores of seda-
tion. They also correlate well with the effect-site
concentration of anaesthetic agent and between
each other. However, high correlation between two
measures does not necessarily mean good agree-
ment. Hence, although correlating well, differences
of more than 20 units between BIS™ and SE have
been reported to occur frequently (68). The agree-
ment between two measures can be good in a given
clinical situation (e.g. the awake state) and poor in
another (e.g. at the time of the loss of conscious-
ness). Discrepancies between measures can be due
to scales differences, or related to the site of record-
ing, to differences in calculation algorithms and
delays to obtain the value, as well as in shapes of
the relationship between a given DHCA index and
the hypnotic level. Finally, EMG activity can also
differently affect the value of the compared indices.
Therefore, DHCA indices can not be used inter-
changeably and specific reference values should be
defined for each of them.
PATIENTS AND PRACTITIONERS KNOWLEDGE AND EXPEC-
TATIONS
As demonstrated in an Australian study, the
problem of awareness is often underestimated by
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the anaesthesiologists, especially the more senior
ones, although many of them have already experi-
enced a patient with awareness (69). Before the
efficacy of DHCA monitoring in preventing intra
operative awareness had been demonstrated, scepti-
cal anaesthesiologists were claiming that they were
prepared to use DHCA monitoring more widely if it
was demonstrated to reduce the incidence of aware-
ness. The future will tell us if this assertion is true.
The patient’s knowledge about the problem of
awareness is weak. Only half of the patients have
already heard about awareness, mainly through the
media. Many patients are anxious about it but few
would pay for a proven awareness monitor. The
propensity of willing to pay depends on the per-
ceived risk and on the occurrence of a previous
awareness episode (70). However, patients still
assign an intrinsic base value for the possibility of
awareness (71) and some studies highlight the lack
of information and knowledge both of patients and
anaesthesiologists. On the other hand, some practi-
tioners are not convinced that DHCA monitors are
valuable and should be used to reduce the risk of
intra operative awareness during general anaesthe-
sia (34).
COST-BENEFIT ESTIMATION
The average cost of DHCA monitors is high,
and, at the present time, approximates 8000 Euros.
Furthermore, disposable specific sensors are pur-
chased at a cost approaching 16 euros per unit. If
turnover of the stock is not fast enough, those sen-
sors can be rapidly out of date and become unus-
able. There is no real difference between one type
of monitor or another in terms of cost (45, 46). Cost
saving when using those devices is not easy to eval-
uate. Although reducing the amount of anaesthetic
agents given to patients and hastening recovery, the
cost savings associated to these advantages do not
exceed the supplementary costs associated to
DHCA monitoring when the procedure is short (72-
74). However, improvement of the quality of anaes-
thesia and prevention of awareness are not money
quantifiable at an individual scale.
CONCLUSIONS
DHCA monitors are certainly interesting
tools. They undoubtedly improve the quality of
anaesthesia if they are used in the right way. This
requires a good knowledge of the information they
can provide, and of their limitations. When using
them, anaesthesiologists must know that the total
cost of anaesthetic management will increase, par-
ticularly for short procedures. Future research will
highlight other advantages linked to their use, par-
ticularly in the domain of intra operative awareness
prevention, nociceptive-anti-nociceptive balance
appreciation, development of closed-loop systems,
and prevention of the risks associated to a too deep
anaesthesia.
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